Atara Biotherapeutics
ATRA
114 hedge funds and large institutions have $1.7B invested in Atara Biotherapeutics in 2018 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 15 reducing their positions, and 10 closing their positions.
471% more call options, than puts
Call options by funds: $32.2M | Put options by funds: $5.64M
290% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 10
233% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 15
213% more capital invested
Capital invested by funds: $542M → $1.7B (+$1.16B)
33% more funds holding
Funds holding: 86 → 114 (+28)
0.59% more ownership
Funds ownership: 3.9% → 4.49% (+0.59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$159M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$61.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$57M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$51.8M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$39.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$62.4M |
| 2 |
RI
RTW Investments
New York
|
-$10.1M |
| 3 |
1WCM
12 West Capital Management
New York
|
-$8.02M |
| 4 |
NC
Nexthera Capital
New York
|
-$5.19M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$4.92M |
ATRA Hedge Fund Activity: Q1 2018 in Review
114 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2018, worth a combined $1.7B — up 213% from $542M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ATRA positions and 10 closed out — a net gain of 29 holders — while 50 added to existing stakes and 15 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $159M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $62.4M.
- 114 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2018, up from 86 in Q4 2017.
- Funds reported $1.7B of Atara Biotherapeutics stock for Q1 2018, up 213% quarter-over-quarter.
- 39 funds opened new Atara Biotherapeutics positions in Q1 2018 and 10 closed out, a net change of +29 holders.
- The largest Atara Biotherapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $159M added.
- The largest Atara Biotherapeutics seller in Q1 2018 was ArrowMark Colorado Holdings, an estimated $62.4M sold.
Based on aggregated 13F filings for Q1 2018.